Objective: To identify whether ischemia modified albumin (IMA) is non traditional risk marker for peripheral arterial disease, and to determine whether there is an association between serum rschemia-modified albumin and the risk factor profile in type 2 diabetic patients with peripheral arterial disease.
Methods: 30 patients with type 2 diabetes mellitus (15 patients with peripheral arterial disease (PAD), and 15 patients without peripheral arterial disease), beside 15 healthy subjects, age and sex matched as a control group were enrolled in the study. The basal ischemia-modified albumin (IMA) levels, clinical parameters and risk factors for peripheral arterial disease were measured and analyzed by multiple logistic analysis.
Exclusion Criteria: Patients with liver, kidney diseases, ischemic events (CVS and IHD), infection, corticosteroid therapy or malignancy.
Diagnoses of peripheral arterial disease were confirmed by measuring ankle-brachial pressure index (AB1), diagnosis of peripheral arterial disease was based on an ankle-brachial pressure index <0.9 or >1.3 in cither leg.
Results: There were significant increases in the duration of diabetes mellitus, random blood sugar (RBS), total choles¬terol, triglycerides, low density lipoprotein and IMA in diabetic patients with PAD than without PAD. While ABI was signif¬icantly decreased (p<0.001) in diabetic patients with PAD than without PAD.
Multiple logistic analysis indicated that increase duration of diabetes, random blood sugar (RBS), ischemia modified albumin, and decrease ABI were independent risk factors for peripheral arterial disease in diabetic subjects.
Conclusion: The baseline ischemia-modified albumin levels were significantly higher and positively correlated with HbAlc and RBS level, duration of the disease and ABI in type 2 diabetic patients with peripheral arterial disease. Ischemia-modified albumin was a risk marker for peripheral arterial disease. Taken together, these results might be helpful for monitoring diabetic peripheral arterial disease.